Results of Serodus’ SER140 in diabetic mice will be published in the Journal of Diabetic Research

Oslo, Norway, 12 January 2016: Serodus ASA (SER) (Oslo Axess) today announced that the manuscript “The IL-1b receptor antagonist SER140 postpones the onset of diabetes in female non-obese diabetic mice” has been accepted for publication in in the Journal of Diabetic Research and will shortly be available electronically. Serodus’ compound, SER140 significantly delays the development of diabetes in the NOD mice, a well-recognized experimental diabetes model. 

“Serodus is very proud of the acceptance in a highly esteemed journal of the first SER140 publication in diabetes, one of Serodus prioritized research area. We are looking forward to discuss these results with both investors and potential licensee” says Eva Steiness, CEO in Serodus.

For additional information of a more detail biography of the scientific advisors, please visit www.serodus.com or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.